Changjiang Pharmaceutical Group Co., Ltd.

SZSE:300391 Stock Report

Market Cap: CN¥1.9b

Changjiang Pharmaceutical Group Past Earnings Performance

Past criteria checks 0/6

Changjiang Pharmaceutical Group's earnings have been declining at an average annual rate of -8%, while the Auto Components industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 0.2% per year.

Key information

-8.0%

Earnings growth rate

-7.9%

EPS growth rate

Auto Components Industry Growth3.8%
Revenue growth rate0.2%
Return on equity-115.3%
Net Margin-242.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Shares Climb 53% But Its Business Is Yet to Catch Up

Nov 14
Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Shares Climb 53% But Its Business Is Yet to Catch Up

Revenues Not Telling The Story For Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) After Shares Rise 45%

Sep 30
Revenues Not Telling The Story For Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) After Shares Rise 45%

Investors Don't See Light At End Of Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Tunnel And Push Stock Down 31%

Aug 11
Investors Don't See Light At End Of Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) Tunnel And Push Stock Down 31%

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Jun 17
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Apr 17
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%

Feb 27
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%

Revenue & Expenses Breakdown

How Changjiang Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300391 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24277-6712995
30 Jun 24795-7343686
31 Mar 241,120-6303387
31 Dec 231,198-6063008
30 Sep 231,215-16724012
30 Jun 231,099-718811
31 Mar 231,207-6118120
01 Jan 231,615-2321326
30 Sep 221,966-2022333
30 Jun 222,056-7526139
31 Mar 222,122425937
01 Jan 222,3624924839
30 Sep 212,38812121341
30 Jun 212,14311717843
31 Mar 211,8749016646
31 Dec 201,2152514143
30 Sep 20784-69618846
30 Jun 20636-72318347
31 Mar 20591-70016344
31 Dec 19725-67017648
30 Sep 197632213637
30 Jun 198978113436
31 Mar 1998811514134
31 Dec 1888110212733
30 Sep 1894712314032
30 Jun 1889810311452
31 Mar 188298011344
31 Dec 177447010934
30 Sep 17564538329
30 Jun 1740935890
31 Mar 172415800
31 Dec 162354770
30 Sep 162146700
30 Jun 16194-1730
31 Mar 161954620
31 Dec 151915600
30 Sep 1521411640
30 Jun 1523121520
31 Mar 1524426540
31 Dec 1424329500
30 Sep 1425435470
30 Jun 1424834490
31 Mar 1425434500
31 Dec 1325535500

Quality Earnings: 300391 is currently unprofitable.

Growing Profit Margin: 300391 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300391 is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.

Accelerating Growth: Unable to compare 300391's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300391 is unprofitable, making it difficult to compare its past year earnings growth to the Auto Components industry (10.5%).


Return on Equity

High ROE: 300391 has a negative Return on Equity (-115.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 00:58
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Changjiang Pharmaceutical Group Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xue DengTianfeng Securities Brokerage Co., Ltd